We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Plasma Biomarker Linked to Middle Age Cognitive Decline

By LabMedica International staff writers
Posted on 21 Jul 2020
Print article
Image: Three-dimensional ball-and-stick model of asymmetric dimethylarginine (Photo courtesy of Wikimedia Commons)
Image: Three-dimensional ball-and-stick model of asymmetric dimethylarginine (Photo courtesy of Wikimedia Commons)
Analysis of plasma asymmetric dimethylarginine concentrations showed that elevated levels of this substance could be used as a biomarker to predict worsening cognitive performance in older adults.

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS), an essential enzyme for the synthesis of nitric oxide (NO). Therefore, ADMA may play an important pathophysiological role in the abnormal NO signalling observed in both cardiovascular disease (CVD) and Alzheimer’s disease (AD) and could be a potential target for novel therapeutic interventions.

Previous studies have found that ADMA concentrations were substantially elevated by native or oxidized LDL (low-density lipoprotein) cholesterol. Thus a spiralling effect occurs with high endothelial LDL levels causing greater ADMA values, which in turn inhibit NO production needed to promote vasodilation. The elimination of ADMA occurs through urine excretion and metabolism by the enzyme dimethylarginine dimethylaminohydrolase (DDAH).

While ADMA may be associated with cognitive decline, population‐based evidence has been lacking. In this regard, investigators at Flinders University (Adelaide, Australia) and the University of Aberdeen (United Kingdom) evaluated the association between serum ADMA levels and change in cognitive performance in late‐middle age (from 63 to 67 years) using data obtained in the 1936 Aberdeen Birth Cohort (ABC36) study.

Cognitive performance for this cohort had been established in 1947 when every Scottish schoolchild born in 1936 was tested for mental ability using the Moray House Test. The Aberdeen Birth Cohort study was established to follow-up some of these individuals.

The current study evaluated 93 ABC36 participants who possessed complete data on cognitive performance that had been assessed by using longitudinal Raven’s progressive matrices (RPM) from the years 2000 and 2004 (when they were aged between 63 and 67).

Results revealed that mean plasma ADMA concentrations were approximately 0.4 micromoles per liter lower in those participants with stable or improved RPM scores over follow‐up compared with participants whose cognitive performance worsened. An increase of 0.06 micromoles per liter in ADMA at 63 years of age was associated with an average reduction in RPM of 1.26 points after four years. Thus, raised plasma ADMA concentrations predicted worsening cognitive performance after approximately four years in this cohort of adults in late‐middle age.

"In the first longitudinal study, ADMA levels measured in the year 2000 (at participants' age 63 years) was associated with decline in cognitive performance assessments after four years," said contributing author Dr. Arduino Mangoni, head of clinical pharmacology at Flinders University. "Therefore the results of this study suggest, that ADMA, an easily measurable marker of atherosclerosis and cardiovascular risk, could be an early indicator of cognitive decline in old age - and possibly dementia."

The study linking asymmetric dimethylarginine and cognitive decline was published in the May 25, 2020, online edition of the journal International Journal of Geriatric Psychiatry.

Related Links:
Flinders University
University of Aberdeen



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.